- Sonnet BioTherapeutics (NASDAQ:SONN) has successfully completed a multiple dose non-human primate (NHP) study of SON-080 (low-dose recombinant fully human Interleukin 6, or IL-6).
- The toxicology study demonstrated a wide safety margin with no adverse effects observed in male or female cynomolgus monkeys at the doses tested.
- No mortality occurred in animals dosed at the three dose levels tested.
- No test item-related clinical signs, nor changes in body weight, food consumption, ophthalmological examination and cardiovascular and urinary parameters were observed.
- No test item-related changes in clinical chemistry parameters at 1 µg/kg in both sexes and at 3 µg/kg in females were observed.
- As a next step, the Company intends to determine human equivalent doses. Sonnet is planning to initiate pilot scale efficacy clinical trials during H2 2021 for Chemotherapy Induced Peripheral Neuropathy, followed by Diabetic Peripheral Neuropathy.
- Shares up 8% premarket.